

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  01D0699979	<b>(X3) Date Survey Completed</b>  08/06/2019
<b>Name of Provider or Supplier</b>  Anniston Family Practice	<b>Street Address, City, State</b>  400 East 8th Street, Anniston, AL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a review of the Casper reports (#153/#155) and a review of the MLE (Medical Laboratory Evaluation) proficiency testing records, the surveyor determined the laboratory failed to successfully participate in proficiency testing for two consecutive testing events for WBC (White Blood Cell) Differential. This affected 2019 Events MLE M1 and MLE M2. The findings include: 1. A review of the Casper reports revealed the laboratory failed WBC Differential testing for two consecutive testing events in 2019, MLE M1 (73 %) and MLE M2 (66 %). 2. Review of the MLE proficiency testing records revealed the laboratory scored 73 % for the WBC Differential for Event 2019 MLE M1 and 66 % for 2019 MLE M2. 3. These two</p>

consecutive failures resulted in the laboratory's initial unsuccessful proficiency testing participation.

**D2130**

HEMATOLOGY  
CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a review of the Casper reports (#153 and #155) and a review of the MLE (Medical Laboratory Evaluation) proficiency testing records, the surveyor determined the laboratory failed WBC (White Blood Cell) Differential testing for two consecutive testing events, 2019 MLE M1 and MLE M2. These failures resulted in unsuccessful performance in proficiency testing by the laboratory. The findings include: 1. A review of the Casper reports revealed the laboratory failed WBC Differential testing for two consecutive testing events in 2019, MLE M1 (73 %) and MLE M2 (66 %). 2. Review of the MLE proficiency testing records revealed the laboratory scored 73 % for the WBC Differential for Event 2019 MLE M1 and 66 % for 2019 MLE M2. 3. These two consecutive failures (unsatisfactory performance) resulted in the laboratory's initial unsuccessful proficiency testing participation.